Nesvacumab

Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1. Nesvacumab can be used in vascular researches[1][2].

Product Specifications

CAS Number

[1296818-77-3]

UNSPSC

12352203

Target

Tie

Type

Inhibitory Antibodies

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Cardiovascular Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/nesvacumab.html

Purity

99.11

Solubility

H2O

Smiles

[Nesvacumab]

Molecular Weight

(144.86 kDa)

References & Citations

[1]Kyriakos P Papadopoulos, et al. A Phase I First-in-Human Study of Nesvacumab (REGN910), a Fully Human Anti-Angiopoietin-2 (Ang2) Monoclonal Antibody, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2016 Mar 15;22 (6) :1348-55.|[2]Vakili S, et al. Angiopoietin-2 reverses endothelial cell dysfunction in progeria vasculature. Aging Cell. 2025 Feb;24 (2) :e14375.